KMID : 1038820160190020116
|
|
Pediatric Gastroenterology, Hepatology & Nutrition 2016 Volume.19 No. 2 p.116 ~ p.122
|
|
Adalimumab Treatment in Pediatric-Onset Crohn¡¯s Disease Patients after Infliximab Failure: A Single Center Study
|
|
Song Won-Jae
Kang Ben Choi So-Yoon Choe Yon-Ho
|
|
Abstract
|
|
|
Purpose: We aimed to investigate the efficacy and safety of adalimumab in pediatric-onset Crohn¡¯s disease patients who had failed treatment with infliximab.
Methods: In this retrospective study, patients included were those who had been diagnosed with Crohn¡¯s disease before 18 years old, and had received treatment with adalimumab after infliximab failure. The efficacy of adalimumab treatment was investigated at 1 month and 1 year, and adverse events that had occurred during treatment with adalimumab were explored.
Results: Ten patients were included in this study. The median duration from diagnosis to adalimumab treatment was 5.5 years (range: 2.4-7.9 years). At 1 month after adalimumab initiation, 80% (8/10) of patients showed clinical response, and 40% (4/10) achieved clinical remission. At 1 year, 71% (5/7) of patients showed clinical response, and 43% (3/7) were under clinical remission. Among the total included patients, 5 patients (50%) showed clinical response at 1 year. Primary non-response to adalimumab was observed in 2 patients (20%), and secondary failure to adalimumab was observed in 3 patients (30%) during 1 year treatment with adalimumab. No serious adverse event had occurred during adalimumab treatment.
Conclusion: Adalimumab was effective for 1 year without serious adverse events in half of pediatric-onset Crohn¡¯sdisease patients who had failed treatment with infliximab.
|
|
KEYWORD
|
|
Pediatric Crohn¡¯s disease, Adalimumab, Antibody to infliximab
|
|
FullTexts / Linksout information
|
|
|
|
Listed journal information
|
|
|